MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clinre.2022.101980

Медицинская библиотека · Clinics and research in hepatology and gastroenterology · 2022

Clinical course of inflammatory bowel disease and impact on liver disease outcomes in patients with autoimmune sclerosing cholangitis.

Nayagam Jeremy S, Mandour Mandour O, Taylor Alison, Heneghan Michael A, Dubois Patrick Ca, Hayee Bu, Lee Huey Miin, Vadamalayan Babu, Samyn Marianne, Joshi Deepak, Kent Alexandra J

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND & AIMS: Autoimmune sclerosing cholangitis (ASC) is a childhood sclerosing cholangitis frequently associated with inflammatory bowel disease (IBD). We describe the IBD phenotype in ASC patients and associated liver disease outcomes.

METHODS

Single center retrospective observational review of ASC patients, with a control population of pediatric IBD. Demographic and clinical parameters were obtained. Clinical endpoints were escalation of IBD therapy (biologic or colectomy) and transplant-free survival.

RESULTS

In 93 ASC patients (53.8% female) and median follow up of 172 months: 70% had IBD, 25.8% underwent liver transplant. Median age at liver transplant was 21.7 years, at 131 months from ASC diagnosis. There was no association between presence of IBD and transplant-free survival, whilst those requiring second-line immunomodulators for ASC had poorer long-term liver prognosis. During follow-up 22 (33.8%) ASC-IBD required biologic or colectomy. On multivariate analysis ASC was associated with a lower risk of escalation of IBD therapy (HR 0.14, 95% CI 0.05-0.42; P=.001), including biologic therapy (HR 0.21, 95% CI 0.08-0.55, P=.002), but not colectomy on univariate analysis (HR 1.54, 95% CI 0.43-5.44, P=.51).

CONCLUSIONS

IBD is common in ASC and during longterm follow up a third of ASC-IBD required escalation of IBD therapy; however ASC-IBD was lower risk compared to IBD alone. IBD does not appear to impact on transplant-free survival in patients with ASC, however second-line immunomodulators for ASC are associated with poorer IBD and liver outcomes.

Для цитирования: Nayagam Jeremy S, Mandour Mandour O, Taylor Alison, Heneghan Michael A, Dubois Patrick Ca, Hayee Bu, Lee Huey Miin, Vadamalayan Babu, Samyn Marianne, Joshi Deepak, Kent Alexandra J. Clinical course of inflammatory bowel disease and impact on liver disease outcomes in patients with autoimmune sclerosing cholangitis.. Clinics and research in hepatology and gastroenterology. 2022. DOI: 10.1016/j.clinre.2022.101980.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.